



MARKET RELEASE

7 February 2012

Probiomics Limited

TRADING HALT

The securities of Probiomics Limited (the "Company") will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company regarding the results of its general meeting of 7 February 2012 to consider the takeover of Hunter Immunology Limited.

In accordance with ASX's requirements for compliance with Chapter 11 of the Listing Rules, if shareholders' approval is obtained, it is expected that the Company's securities will be suspended from quotation immediately following such approval and will remain suspended until the Company has complied with Chapters 1 and 2 of the Listing Rules.

Security Code: PCC

A handwritten signature in black ink, appearing to read 'Elvis Onyura', is written over a circular stamp that contains a grid pattern.

Elvis Onyura
Adviser, Listings (Sydney)

6 February 2012

Our Ref: DPS:PRO005/4001

TELEPHONE +61 2 8915 1000
FACSIMILE +61 2 8916 2000

Level 12

60 Carrington Street
Sydney NSW Australia
GPO Box 1433 Sydney
NSW 2001 Australia
DX 262 Sydney
ABN 55 365 334 124

ASX Limited
Exchange Centre
20 Bridge Street
SYDNEY NSW 2000

By Email

Attention: Elvis Onyura and Adrian Smythe

Dear Sirs

Probiomics Limited ACN 084 464 193

We have been instructed on behalf of our client Probiomics Limited (ASX Code: PCC) (**Probiomics**) to request ASX to exercise its discretion under:

- (a) Listing Rule 17.1 to place a trading halt on the securities of Probiomics from quotation, commencing immediately after close of market on Monday 6 February 2012, being the day immediately before the date of Probiomics' general meeting, which is proposed to be held at 11am on Tuesday 7 February 2012 (**Meeting**) and ending immediately after the close of the Meeting (**Trading Halt**); and
- (b) Provided the "Essential Resolutions" proposed at the Meeting are passed, Listing Rules 11.13 and 17.2 to suspend the securities of Probiomics from quotation (**Voluntary Suspension**), commencing immediately after the end of the trading halt referred to in paragraph (a) and ending immediately after close of market on the day immediately before the date of re-instatement of the securities of Probiomics to official quotation on ASX (**Re-admission Date**).

In accordance with ASX Listing Rules 17.1 and 17.2, we advise ASX as follows:

- (a) the reason for this request for the Trading Halt and Voluntary Suspension is to permit Probiomics to, inter alia, satisfy the requirements of Listing Rule 11.1. As you are aware, Probiomics is proposing to hold the Meeting to obtain shareholder approval to a series of transactions necessary to complete its takeover bid for Hunter Immunology Limited and to effect the resulting significant change to the scale of Probiomics' activities;
- (b) Probiomics seeks:
 - (i) the Trading Halt to continue until immediately after the close of the Meeting; and


ASX Limited

6 February 2012

- (ii) Voluntary Suspension to continue until immediately after close of market on the day immediately before the Re-admission Date;
- (c) in regards to the event that we expect to end the requested Trading Halt and Voluntary Suspension, please see our comments described in paragraph (b) immediately above;
- (d) we are not aware of any reason why the requested Trading Halt and Voluntary Suspension should not be granted; and
- (e) we are not aware of any other information necessary to inform the market about the requested Trading Halt and Voluntary Suspension or that has been requested by the ASX.

If you have any queries, please do not hesitate to contact the writer or Belle Jing on (02) 8915 1048 or belle.jing@addisonslawyers.com.au.

Yours faithfully



David P. Selig

Partner

Direct Line: (02) 8915 1010

Direct Fax: (02) 8916 2010

Email: david.selig@addisonslawyers.com.au